Human Genome Sciences, Inc. has signed an exclusive worldwide licensing agreement with Novartis for the development and commercialization of Albuferon for chronic hepatitis C and all other uses. The two companies will commercialize Albuferon in the U.S. and will share the commercialization costs and profits. Novartis will be responsible for commercialization outside the U.S. and will pay HGS a royalty on those sales. HGS and Novartis will share clinical development costs. HGS will receive ...